TOPIC : Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System
|Publication date:||14 October 2015|
|Types of action:||RIA Research and Innovation action|
|DeadlineModel: Opening date:||two-stage 15 October 2015||Deadline: 2nd stage Deadline:||
08 December 2015 17:00:00
24 May 2016 17:00:00
|Time Zone : (Brussels time)|
Topic DescriptionSpecific Challenge:
The aim of this topic is to develop innovative approaches for biomaterials for health that are easily transferable from industry to the clinic and based on new methodologies directed to the improvement of the treatment and prognosis of demyelination disorders (one specific disorder to be chosen), where regrowth and regeneration of affected areas of the nervous system is the key to successful therapy. These disorders are often of chronic duration and associated with increasing levels of disability. In the European Union, at least 1 000 000 people are affected with these disorders and many more times than that world-wide. They are often diagnosed between the ages of 20 and 40 when families and careers are developing and can represent the most common cause of disability affecting young adults, thereby having a strong economic impact for society in terms of healthcare costs.Scope:
Proposals should focus on the development of new multifunctional biomaterials, as part of eventual Medical Devices or Advanced Therapies, so that they can function as effective eventual therapeutic interventions. They can include biocompatible and biodegradable biomaterials as part of minimally invasive treatments and theragnostic materials. Funding for the development of new drug candidates for these conditions or for any form of clinical trial will not be considered.
The development of new integrated experimental and computational approaches aimed to describe interface processes and their determinants should be considered as key step for the design of safe and performing biomaterials. Experimental protocols should be planned taking due account of current good laboratory practice (GLP) and ISO guidelines. Manufacturing processes will need to be addressed, including up scaling, good manufacturing practice (GMP), process analytical technology (PAT), technology transfer and regulatory work in respect of relevant regulations as appropriate. At least one type of tissue engineering construct should be delivered at the end of the research project together with a proof of concept of its therapeutic potential and preclinical validation.
In order to ensure relevance and impacts of the research efforts, the active participation of industrial partners and clinicians represents an added value to the proposals and this will be reflected in the evaluation under the criterion “Impact”. A multidisciplinary approach is preferred; taking into account both surgical, minimally invasive and pharmacological approaches, as well as prevention and rehabilitation strategies, including robotics if necessary. The expected results should improve the quality of life of the affected population and their careers. They should be measurable even for optimising research costs of the enterprises and for reducing time-to-market of new products. The project should include training and dissemination activities. As relevant, the proposed activities should address sex and gender specific aspects.
The implementation of this topic is intended to start at TRL 3 and target TRL 5.
This topic is particularly suitable for SMEs.
The Commission considers that proposals requesting a contribution from the EU between EUR 5 and 8 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.Expected Impact:
- Innovative bio/nano-materials for the treatment of patients with demyelination disorders of the Central Nervous System, improving their quality of life due to minimally invasive action and/or longer duration of implants and devices;
- reduced direct and indirect costs linked to these diseases and their treatment;
- enhance competitiveness of the biomaterials and biomedical industries in the EU, in particular through technology transfer effects on biotechnology companies, with particular regard to SMEs and new forms of cooperation between academia, research centres and the private sectors. Such effects should be balanced to match sustainability principles and values, and to enforce competitiveness in terms of reducing time-to-market and trial costs for European industries;
- Dissemination of results, contributing to increase social awareness about more efficient and less costly therapies – based upon innovative approaches and broader accessibility – with improved patient compliance.
Proposals should include a business case and exploitation strategy, as outlined in the Introduction to the LEIT part of this Work Programme.Cross-cutting Priorities:
 As defined by Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to Active Implantable Medical Devices (90/385/EEC) (OJ L 189, 20.7.1990, p. 17) (as amended), Council Directive 93/42/EEC of 14 June 1993 concerning Medical Devices (OJ L 169, 12.7.1993, p. 1) (as amended) and Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on In Vitro Diagnostic Medical Devices (OJ L 331, 7.12.1998, p. 1) (as amended) and with the relevant Implementing Measures and all succeeding measures.
 As defined by Regulation (EC) No 1394/2007 on advanced therapy medicinal products (gene therapy, stem cell therapy and tissue engineering)
As defined by Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to Active Implantable Medical Devices (90/385/EEC) (OJ L 189, 20.7.1990, p. 17) (as amended), Council Directive 93/42/EEC of 14 June 1993 concerning Medical Devices (OJ L 169, 12.7.1993, p. 1) (as amended) and Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on In Vitro Diagnostic Medical Devices (OJ L 331, 7.12.1998, p. 1) (as amended) and with the relevant Implementing Measures and all succeeding measures.
As defined by Regulation (EC) No 1394/2007 on advanced therapy medicinal products (gene therapy, stem cell therapy and tissue engineering)
See definition of the 'gender dimension approach' in the introduction of this Work Programme part.
Topic conditions and documents
Please read carefully all provisions below before the preparation of your application.
- LIST OF COUNTRIES and APPLICABLE RULES FOR FUNDING
described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects (follow the links to Australia, Brazil, Canada, China, Hong Kong &Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan).
- ELIGIBILITY and ADMISSIBILITY CONDITIONS
described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme , with the following exceptions:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4.
The overall threshold, applying to the sum of the three individual scores, will be 12.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except that proposals will be ranked on the basis of individual scores for the Impact criterion before the Excellence criterion.
In case of equal overall scores in the ranked list, the priority order of proposals will be established in accordance with part H of the General Annexes, except, when comparing ex aequo proposals of different topics, the proposals will be ranked first according to the position in the topic ranked lists
3.2 Submission and evaluation process: Guide to the submission and evaluation process
- INDICATIVE TIMETABLE for EVALUATION and GRANT AGREEMENT
Information on the outcome of two-stage evaluation:
For stage 1: maximum 3 months from the deadline for submission.
For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
- PROVISIONS, PROPOSAL TEMPLATES and EVALUATION FORMS
for the type of action under this topic
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
H2020 General MGA -Multi-Beneficiary
Annotated Grant Agreement
- ADDITIONAL PROVISIONS
Horizon 2020 budget flexibility
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Financial support to Third Parties – where a topic description foresees financial support to Third Parties, these provisions apply.
- OPEN ACCESS
must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
- ADDITIONAL DOCUMENTS
Legal basis: Horizon 2020 - Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
H2020 Work Programme 2016-17: Introduction
H2020 Work Programme 2016-17: Introduction to Leadership in enabling and industrial technologies (LEITs)
H2020 Work Programme 2016-17: Nanotechnologies, advanced materials, advanced manufacturing and processing, biotechnology
H2020 Work Programme 2016-17: Cross-cutting activities (Focus Areas)
H2020 Work Programme 2016-17: Dissemination, Exploitation and Evaluation
H2020 Work Programme 2016-17: General Annexes
No submission system is open for this topic.
National Contact Points (NCP) - contact your NCP for further assistance.
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
Partner Search Services help you find a partner organisation for your proposal.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
H2020 Online Manual your online guide on the procedures from proposal submission to managing your grant.
Participant Portal FAQ – Submission of proposals.
IT Helpdesk- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues